Visit https://www.peervoice.com/CCM860 to view the entire programme with slides. After completing “Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings”, participants will be able to: Explain the mechanistic rationale for investigating the therapeutic potential of TROP2-targeted treatment approaches in early treatment and disease-stage settings for triple-negative breast cancer (TNBC); Differentiate between TROP2-targeted antibody-drug conjugates on construct and mode of action and discuss the potential clinical significance of these differences; and Evaluate the latest clinical data for TROP2-targeted therapeutic strategies in early treatment lines and/or disease-stage settings of TNBC.

Visit https://www.peervoice.com/FCE860 to view the entire programme with slides. After completing “Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target”, participants will be able to: Recall the cellular role of p53 in regulating apoptosis, and how this is disrupted in patients with myelofibrosis; and Assess the clinical significance of trial data evaluating the safety and efficacy of MDM2 inhibition (as monotherapy or in combination with other agents) in the therapeutic management of patients with TP53-wt myelofibrosis.

Visit https://www.peervoice.com/MQC860 to view the entire programme with slides. After completing “Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy”, participants will be able to: Recognize unmet needs surrounding the management of peripheral T-cell lymphoma (PTCL), including the impact of the disease on patient quality of life (QoL); Assess the clinical significance of clinical trial data evaluating the safety and efficacy of novel treatments for the management of relapsed/refractory (R/R) PTCL; and Implement current consensus best practice approaches to the management of R/R PTCL.

Visit https://www.peervoice.com/USJ860 to view the entire programme with slides. After completing “Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025”, participants will be able to: Describe recent clinical trial data on novel targeted therapies for HER2-mutant NSCLC; and Evaluate recent clinical trial data on novel HER2-targeted therapies within the wider treatment landscape of NSCLC.

Visit https://www.peervoice.com/XKC860 to view the entire programme with slides. After completing “Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC”, participants will be able to: Evaluate novel data presented at ESMO 2025 related to the use of androgen receptor pathway inhibitors (ARPIs) in the management of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC), including relevant efficacy and safety data, subgroup analyses, and real-world evidence; and Assess the potential implications of recently presented findings for the clinical care of individuals living with mHSPC or nmCRPC.

Visit https://www.peervoice.com/YHE860 to view the entire programme with slides. After completing “Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO”, participants will be able to: Evaluate emerging updates on antibody-drug conjugates (ADCs) for the treatment of HER2+ breast cancer; Recall the latest evidence for ADCs in the treatment of HR+ and/or triple-negative breast cancer; and Assess the implications of the latest clinical evidence for approved ADCs in breast cancer in context of current treatment guidelines.

Visit https://www.peervoice.com/EAJ860 to view the entire programme with slides. After completing “Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies”, participants will be able to: Recognize guideline-recommended best practices in the diagnostic assessment and therapeutic management of patients presenting with blastic plasmacytoid dendritic cell neoplasm (BPDCN); Implement evidence-based best practice approaches to the diagnosis of BPDCN in patients presenting with symptoms of this condition; and Formulate appropriate management plans for patients with BPDCN, including selecting initial therapy, identifying candidates for stem cell transplant, and providing adverse event monitoring and management plans in patients receiving targeted therapy.

Visit https://www.peervoice.com/ZUC860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC”, participants will be able to: Utilise appropriate diagnostic technologies to overcome challenges in accurately characterising molecular alterations in patients with NTRK fusion-positive and HER2-mutant advanced NSCLC; Differentiate between precision oncology therapies used in patients’ management of NTRK fusion-positive advanced NSCLC; Distinguish between the study populations of clinical trials examining emerging targeted therapies in patients with advanced NSCLC harbouring HER2-activating mutations from studies examining other HER2 aberrations; and Describe the recent data and clinical significance associated with trials examining emerging targeted therapies in patients with advanced NSCLC harbouring HER2-activating mutations.

Visit https://www.peervoice.com/DHX860 to view the entire programme with slides. After completing “Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients”, participants will be able to: Implement recommended patient communication approaches when discussing mutational testing in metastatic castration-resistant prostate cancer (mCRPC), including what tests involve, what impact a positive result means for treatment options, and how to empower patients to make informed decisions about their treatment plan

Visit https://www.peervoice.com/RRA860 to view the entire programme with slides. After completing “Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease”, participants will be able to: Identify persistent gaps in the provision of patient-centred care for metastatic hormone-sensitive prostate cancer (mHSPC); Assess novel evidence related to PSA response and its association with clinical outcomes in patients with mHSPC; Evaluate the efficacy and safety of treatment regimens for mHSPC based on patient and disease characteristics such as age, disease volume, and disease risk; and Identify patient comorbidities, concomitant drug regimens, and preferences that may inform treatment planning in mHSPC.

Visit https://www.peervoice.com/TQR860 to view the entire programme with slides. After completing “Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?”, participants will be able to: Recognise the rationale behind TROP2 as a therapeutic target in NSCLC; Recall the results of clinical trials assessing the safety and efficacy of TROP2-directed therapy across different types of NSCLC, including non-oncogene-addicted, EGFR-mutant and ALK-rearranged NSCLC; and Assess the clinical relevance of subgroup analyses evaluating the effect of TROP2-directed therapy in specific types of NSCLC (eg, EGFR-mutant NSCLC that has progressed after initial TKI therapy).

Visit https://www.peervoice.com/EMZ860 to view the entire programme with slides. After completing “Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making”, participants will be able to: Evaluate current efficacy and safety data related to the use of targeted therapies in the treatment of advanced or metastatic biliary tract cancer (BTC); Apply best practices and guideline recommendations for timely molecular testing of BTC; and Design personalised treatment regimens for individual patients with BTC based on current evidence and guidelines.

Visit https://www.peervoice.com/BEZ860 to view the entire programme with slides. After completing “Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients”, participants will be able to: Assess the clinical implications of clinical trial data and real-world evidence evaluating available treatment regimens for the first-line management of advanced bladder cancer; and Formulate individualised management plans for the first-line management of advanced bladder cancer considering factors such as patient age, fitness, goals of therapy and eligibility for cisplatin and carboplatin.

Visit https://www.peervoice.com/GWG860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer”, participants will be able to: Recognise the perspectives and concerns of patients with locally advanced, unresectable EGFR-mutated NSCLC in evaluating treatment decisions; Apply practical approaches to facilitate patient understanding of the rationale, implications, and benefits of curative intent treatment strategies in the management of locally advanced, unresectable EGFR-mutated NSCLC; and Implement practical communication approaches to support patients with locally advanced, EGFR-mutated NSCLC in making decisions about treatment.

Visit https://www.peervoice.com/DGN860 to view the entire programme with slides. After completing “Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer”, participants will be able to: Assess the clinical significance of clinical trial data evaluating the safety and efficacy of TROP2-directed antibody-drug conjugate (ADC) therapy in the management of advanced breast cancer; Identify common adverse events associated with the use of TROP2-directed agents in the management of advanced breast cancer; and Implement evidence-based best practices in the monitoring, identification and management of adverse events in patients with advanced breast cancer receiving TROP2-directed therapy.

Visit https://www.peervoice.com/HUF860 to view the entire programme with slides. After completing “Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer”, participants will be able to: Use patient-, disease-, and therapy-specific considerations to guide treatment decision-making for refractory metastatic colorectal cancer (mCRC) that has progressed through recommended systemic regimens; Evaluate patient preferences related to treatment planning and sequencing for refractory mCRC through the application of best practices for patient education and patient-provider communication; and Design patient counseling and follow-up plans that integrate multidisciplinary team (MDT) members and are aimed at promoting adherence to, and tolerance of, chemotherapy regimens.

Visit https://www.peervoice.com/SAU860 to view the entire programme with slides. After completing “Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy”, participants will be able to: Evaluate the available safety and efficacy data from trials examining current and emerging therapies, including combination regimens, in advanced renal cell carcinoma (RCC); Identify and assess adverse events (AEs) associated with combination therapy in patients with advanced RCC; and Apply recommended strategies and incorporate patient preferences in the management of AEs associated with combination therapy in advanced RCC.

Visit https://www.peervoice.com/FKD860 to view the entire programme with slides. After completing “Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer”, participants will be able to: Use the clinical data for folate receptor alpha (FRɑ)-targeted therapies for ovarian cancer to evaluate the need for establishing FRɑ status; Describe the immunohistochemical characteristics of FRɑ-positive ovarian cancer; and Apply guideline recommendations for FRɑ testing and targeted treatment in patients with ovarian cancer.

Visit https://www.peervoice.com/ZXH860 to view the entire programme with slides. After completing “Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed”, participants will be able to: Apply evidence-based and guideline-recommended best practices for molecular testing and identification of disease progression to guide treatment planning and sequencing for refractory metastatic colorectal cancer (mCRC); Evaluate efficacy and safety data for recommended treatments for mCRC that have progressed through prior treatments; and Identify patient-, disease-, and therapy-specific considerations that influence choice of therapy in patients with refractory mCRC.

Visit https://www.peervoice.com/YZR860 to view the entire programme with slides. After completing “Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)”, participants will be able to: Explain the pathogenesis of fetal-neonatal alloimmune thrombocytopenia (FNAIT); Identify individuals with pregnancies suspected to be at risk of FNAIT based on risk factors; Discuss prenatal management and the benefits and limitations of maternal intravenous immunoglobulin (IVIg) for pregnancies at risk of FNAIT; Identify investigative therapies for alloimmunised pregnant individuals at risk of FNAIT and the pathophysiological rationale for their clinical development; Discuss the weight of evidence on the mode and timing of delivery in pregnant individuals at risk of FNAIT; and Discuss the neonatal management of FNAIT and long-term outcomes.